Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AVMXY
Previous Symbol
CUSIPN/A
Phone661-367-9170
Debt
Debt-to-Equity RatioN/A
Current Ratio5.74
Quick Ratio5.45
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.25 million
Price / Sales30.18
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.47 per share
Price / Book2.54
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees37
Outstanding Shares31,650,000
Market Cap$37.66 million
OptionableNot Optionable
AVITA MED LTD/S (OTCMKTS:AVMXY) Frequently Asked Questions
What is AVITA MED LTD/S's stock symbol?
AVITA MED LTD/S trades on the OTCMKTS under the ticker symbol "AVMXY."
What price target have analysts set for AVMXY?
1 equities research analysts have issued 1 year price objectives for AVITA MED LTD/S's shares. Their predictions range from $65.00 to $65.00. On average, they expect AVITA MED LTD/S's stock price to reach $65.00 in the next year. This suggests a possible upside of 5,353.9% from the stock's current price. View Analyst Price Targets for AVITA MED LTD/S.
What is the consensus analysts' recommendation for AVITA MED LTD/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVITA MED LTD/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVITA MED LTD/S.
Has AVITA MED LTD/S been receiving favorable news coverage?
Headlines about AVMXY stock have been trending somewhat positive on Thursday, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AVITA MED LTD/S earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of AVITA MED LTD/S's key competitors?
Some companies that are related to AVITA MED LTD/S include Erytech Pharma (ERYP), Jounce Therapeutics (JNCE), Organovo (ONVO), Fennec Pharmaceuticals (FENC), Nantkwest (NK), Champions Oncology (CSBR), Applied Genetic Technologies (AGTC), Pluristem Therapeutics (PSTI), Cidara Therapeutics (CDTX), Aptose Biosciences (APTO), Aevi Genomic Medicine (GNMX), BioCardia (BCDA), Brainstorm Cell Therapeutics (BCLI), Entera Bio (ENTX) and Arsanis (ASNS).
Who are AVITA MED LTD/S's key executives?
AVITA MED LTD/S's management team includes the folowing people:
- Dr. Michael S. Perry, CEO & Director (Age 59)
- Mr. Timothy Rooney, Chief Admin. Officer
- Mr. Andrew Quick, Sr. VP of Clinical Devel.
- Mr. Adam Kelliher, Consultant
- Mr. Dale A. Sander, Chief Financial Officer (Age 58)
How do I buy shares of AVITA MED LTD/S?
Shares of AVMXY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVITA MED LTD/S's stock price today?
One share of AVMXY stock can currently be purchased for approximately $1.1918.
How big of a company is AVITA MED LTD/S?
AVITA MED LTD/S has a market capitalization of $37.66 million and generates $1.25 million in revenue each year. AVITA MED LTD/S employs 37 workers across the globe.
What is AVITA MED LTD/S's official website?
How can I contact AVITA MED LTD/S?
AVITA MED LTD/S's mailing address is 28159 Avenue Stanford Suite 220, Valencia CA, 91355. The medical device company can be reached via phone at 661-367-9170 or via email at [email protected]
MarketBeat Community Rating for AVITA MED LTD/S (OTCMKTS AVMXY)
MarketBeat's community ratings are surveys of what our community members think about AVITA MED LTD/S and other stocks. Vote "Outperform" if you believe AVMXY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVMXY will underperform the S&P 500 over the long term. You may vote once every thirty days.
